Catalyst Pharmaceuticals (CPRX) Operating Expenses (2010 - 2026)

Catalyst Pharmaceuticals has reported Operating Expenses for 17 years, with the latest figure at $76.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 2.43% year-over-year to $76.2 million; the trailing twelve-month figure through Mar 2026 stood at $329.3 million (up 8.58% YoY), and the FY2025 full-year result was $331.2 million, up 11.67% from the prior year.
• Operating Expenses for Q1 2026 stood at $76.2 million, down from $90.8 million in the prior quarter.
• The five-year high for Operating Expenses was $139.9 million in Q3 2023, with the low at $24.5 million in Q2 2022.
• Historically, Operating Expenses has averaged $66.3 million across 5 years, with a median of $71.4 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Expenses surged 335.18% — and 2024, when it slumped 44.39%.
• Catalyst Pharmaceuticals' Operating Expenses stood at $30.0 million in 2022, then surged by 129.92% to $68.9 million in 2023, then climbed by 14.67% to $79.0 million in 2024, then gained by 14.93% to $90.8 million in 2025, then retreated by 16.1% to $76.2 million in 2026.
• The last three Operating Expenses figures came in at $76.2 million (Q1 2026), $90.8 million (Q4 2025), and $82.1 million (Q3 2025), per Business Quant data.